↓ Skip to main content

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs

Overview of attention for article published in Globalization and Health, May 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
2 blogs
twitter
36 X users

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
Published in
Globalization and Health, May 2014
DOI 10.1186/1744-8603-10-30
Pubmed ID
Authors

Joel Lexchin, Marc-André Gagnon

Abstract

On a per capita basis, Canadian drug costs are already the second highest in the world after the United States and are among the fastest rising in the Organization for Economic Co-Operation and Development. The Comprehensive Economic and Trade Agreement (CETA) between the European Union (EU) and Canada will further exacerbate the rise in costs by:  Committing Canada to creating a new system of patent term restoration thereby delaying entry of generic medicines by up to two years; Locking in Canada's current term of data protection, and creating barriers for future governments wanting to reverse it;  Implementing a new right of appeal under the patent linkage system that will create further delays for the entry of generics.CETA will only affect intellectual property rights in Canada-not the EU. This analysis estimates that CETA's provisions will increase Canadian drug costs by between 6.2% and 12.9% starting in 2023. The Canadian government committed to compensating provinces for the rise in costs for their public drug plans. Importantly, this means that people paying out-of-pocket for their drugs or receiving them through private insurance, will be charged twice: once through higher drug costs and once more through their federal taxes.As drug costs continue to grow, there are limited options available for provincial/territorial governments: restrict the choice of medicines in public drug plans; transfer costs to patients who typically are either elderly or sick; or take money from other places in the health system, and threaten the viability of Canada's single payer system. CETA will therefore negatively impact the ability of Canada to offer quality health care.

X Demographics

X Demographics

The data shown below were collected from the profiles of 36 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 22%
Student > Master 7 14%
Researcher 6 12%
Student > Ph. D. Student 5 10%
Student > Postgraduate 3 6%
Other 6 12%
Unknown 12 24%
Readers by discipline Count As %
Social Sciences 9 18%
Business, Management and Accounting 6 12%
Medicine and Dentistry 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Economics, Econometrics and Finance 3 6%
Other 9 18%
Unknown 14 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2020.
All research outputs
#930,700
of 25,374,647 outputs
Outputs from Globalization and Health
#120
of 1,226 outputs
Outputs of similar age
#8,867
of 241,906 outputs
Outputs of similar age from Globalization and Health
#3
of 34 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,226 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,906 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.